User login
For asymptomatic women at average risk of breast cancer, the American Cancer Society recommends annual mammograms from age 45 until age 54, with a transition to biennial screening mammography starting at age 55, according to new guidelines published Oct. 20.
This is the first time the American Cancer Society (ACS) has updated its breast cancer screening guidelines since 2003. The new version makes several changes, including shifting the start of annual mammography from age 40 to 45 years, and increasing the suggested screening interval for postmenopausal women (JAMA. 2015;314[15]:1599-1614. doi:10.1001/jama.2015.12783).
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
For the first time, the guidelines address the question of when to stop routine mammography, recommending a halt to routine screening for women with a life expectancy under 10 years. The ACS guidelines also recommend against clinical breast examinations at any age.
These changes bring the ACS guidelines more into line with recommendations from the U.S. Preventive Services Task Force, Dr. Nancy L. Keating and Dr. Lydia E. Pace, both of Brigham and Women’s Hospital, Boston, wrote in an editorial accompanying the report.
The two organizations are now in agreement on most recommendations and emphasize that breast cancer screening decisions should be individualized to reflect a woman’s values and preferences, not just her underlying risk. Both sets of recommendations also give greater consideration to the potential harms of mammography: overdiagnosis and overtreatment of indolent breast cancers, as well as false-positive results, additional imaging studies, and unnecessary biopsies.
The ACS updated the guideline after noting that new evidence had accumulated from long-term follow-up of both randomized controlled trials and population-based screening programs. The guideline development group, which included four clinicians, two biostatisticians, two epidemiologists, an economist, and two patient representatives, based its revised recommendations on an independent systemic evidence review of the breast cancer screening literature conducted by the Duke University Evidence Synthesis Group, as well as an analysis screening interval and outcomes from the Breast Cancer Surveillance Consortium.
For asymptomatic women at average risk of developing breast cancer, the ACS guideline makes the following recommendations:
Begin routine annual screening mammography at age 45 years (rather than age 40). Assessing the burden of breast cancer by 5-year rather than 10-year age categories demonstrated that the risk/benefit profiles of women aged 40-44 years differed markedly from those of older women and no longer warranted a recommendation to begin screening at age 40, wrote Dr. Kevin C. Oeffinger of Memorial Sloan Kettering Cancer Center, New York, and his associates in the ACS Guideline Development Group.
However, the ACS encourages clinicians to discuss breast cancer screening with patients “around the age of 40 years.” Women who want to begin annual screening mammography before age 45, based on a clear consideration of the trade-offs, should be given that choice, they wrote.
“Some women will value the potential early detection benefit and will be willing to accept the risk of additional testing,” Dr. Oeffinger and his associates wrote. “Other women will choose to defer beginning screening, based on the relatively lower risk of breast cancer.”
Women aged 45-54 years should receive annual screening mammography and at age 55 women should transition to biennial screening. The relative benefits of annual screening decline after menopause and as women age, and the majority of women are postmenopausal at age 55. At the same time, the relative harms of annual screening increase at this age, because the chance of false-positive results rises as the number of screenings rises. However, women who prefer to continue annual screening after age 55 should be given that opportunity, according to the ACS guidelines.
Women should continue screening mammography as long as their overall health is good and they have a life expectancy of 10 years or longer. Breast cancer incidence continues to increase with age until the age of 75-79 years, and mammography’s sensitivity and specificity improve with increasing age, so screening mammography in this age group will likely reduce breast cancer deaths. However, the authors noted that recent studies have raised concerns that older women with serious, or even terminal disorders, are still subjected to mammograms even though it will not increase their life expectancy or improve their quality of life.
“Health and life expectancy, not simply age, must be considered in screening decisions,” Dr. Oeffinger and his associates wrote.
Clinical breast examination is no longer recommended at any age. Historically, the ACS had advised periodic clinical breast exams for women younger than 40 and annual exams for women 40 and older. But there is no evidence that these exams, whether they are performed alone or in conjunction with mammography, enhance the detection of breast cancer, according to the guidelines.
Given that clinical breast exams are somewhat time consuming, “clinicians should use this time instead for ascertaining family history and counseling women regarding the importance of being alert to breast changes and the potential benefits, limitations, and harms of screening mammography,” the authors wrote.
“This new recommendation should not be interpreted to discount the potential value of clinical breast exams in low-resource settings where mammography screening may not be feasible,” they added.
In the accompanying editorial, Dr. Keating and Dr. Pace called this recommendation “a marked deviation from prior ACS guidelines and a stronger statement than that of the USPSTF,” which states only that the evidence is insufficient to recommend for or against clinical breast exams.
They noted that the majority of women who are diagnosed as having breast cancer “will do well regardless of whether their cancer was found by mammography.”
According to the most recent data, approximately 85% of women in their 40s and 50s who die of breast cancer would have died regardless of mammography screening. And even that 15% relative benefit translates to a very small absolute benefit: only 5 of 10,000 women in their 40s and 10 of 10,000 women in their 50s are likely to have a breast cancer death prevented by regular mammography, Dr. Keating and Dr. Pace wrote (JAMA 2015;314[15]:1569-71).
“It is important to remember and emphasize with average-risk women older than 40 years that there is no single right answer to the question ‘Should I have a mammogram?’ ” they wrote.
The American Cancer Society and the National Cancer Institute sponsored this work. Dr. Oeffinger reported having no relevant financial disclosures, and his associates reported ties to numerous industry sources.
After a little over a decade, the American Cancer Society has published guidelines for screening for the average-risk population. These guidelines provide some flexibility on the initiation of screening mammograms but strongly recommend starting at age 45. As this is an average-risk population, and the rate below this age is low and the rate of false positives is increased (due to dense breast tissue), this recommendation is based on good logic.
The question of frequency of screening is a little more challenging. The authors provide sound rationale for biennial screening after the age of 55. Unfortunately, patients are often hesitant to “skip a year” and this may be harder to enforce. Secondly, practitioners are often slow to adopt new practices as noted by changes in Pap test guidelines. Though this is a reasonable recommendation, it will take some education for patients to understand and will likely be less followed, at least in the beginning.
The final question of when to stop screening is fantastic. As mostly left-brain thinkers, we are often set on an actual age, completely disregarding the health of the patient. As the life expectancy of women in the United States is nearing 80 and many are surviving beyond that age with a high functioning status, consideration of this factor will allow for screening in women who can undergo management (if required) with favorable outcomes. Though practice changes take some time, it is likely that these recommendations will reduce unnecessary costs without impacting outcomes.
Given the substantial reduction in overall mortality, breast cancer screening is an integral part of women’s health. Providers in obstetrics and gynecology are often the primary source of education and the ordering team for breast cancer screening. Thus, it is critical for us to stay current on the recommendations for screening as well as the identification of high-risk women, allowing for well-informed decisions regarding individualized screening.
Dr. Ritu Salani is associate professor in gynecologic oncology at The Ohio State University, Columbus. Dr. Monica Hagan Vetter is a third-year resident in ob.gyn. at The Ohio State University. They reported having no financial disclosures.
After a little over a decade, the American Cancer Society has published guidelines for screening for the average-risk population. These guidelines provide some flexibility on the initiation of screening mammograms but strongly recommend starting at age 45. As this is an average-risk population, and the rate below this age is low and the rate of false positives is increased (due to dense breast tissue), this recommendation is based on good logic.
The question of frequency of screening is a little more challenging. The authors provide sound rationale for biennial screening after the age of 55. Unfortunately, patients are often hesitant to “skip a year” and this may be harder to enforce. Secondly, practitioners are often slow to adopt new practices as noted by changes in Pap test guidelines. Though this is a reasonable recommendation, it will take some education for patients to understand and will likely be less followed, at least in the beginning.
The final question of when to stop screening is fantastic. As mostly left-brain thinkers, we are often set on an actual age, completely disregarding the health of the patient. As the life expectancy of women in the United States is nearing 80 and many are surviving beyond that age with a high functioning status, consideration of this factor will allow for screening in women who can undergo management (if required) with favorable outcomes. Though practice changes take some time, it is likely that these recommendations will reduce unnecessary costs without impacting outcomes.
Given the substantial reduction in overall mortality, breast cancer screening is an integral part of women’s health. Providers in obstetrics and gynecology are often the primary source of education and the ordering team for breast cancer screening. Thus, it is critical for us to stay current on the recommendations for screening as well as the identification of high-risk women, allowing for well-informed decisions regarding individualized screening.
Dr. Ritu Salani is associate professor in gynecologic oncology at The Ohio State University, Columbus. Dr. Monica Hagan Vetter is a third-year resident in ob.gyn. at The Ohio State University. They reported having no financial disclosures.
After a little over a decade, the American Cancer Society has published guidelines for screening for the average-risk population. These guidelines provide some flexibility on the initiation of screening mammograms but strongly recommend starting at age 45. As this is an average-risk population, and the rate below this age is low and the rate of false positives is increased (due to dense breast tissue), this recommendation is based on good logic.
The question of frequency of screening is a little more challenging. The authors provide sound rationale for biennial screening after the age of 55. Unfortunately, patients are often hesitant to “skip a year” and this may be harder to enforce. Secondly, practitioners are often slow to adopt new practices as noted by changes in Pap test guidelines. Though this is a reasonable recommendation, it will take some education for patients to understand and will likely be less followed, at least in the beginning.
The final question of when to stop screening is fantastic. As mostly left-brain thinkers, we are often set on an actual age, completely disregarding the health of the patient. As the life expectancy of women in the United States is nearing 80 and many are surviving beyond that age with a high functioning status, consideration of this factor will allow for screening in women who can undergo management (if required) with favorable outcomes. Though practice changes take some time, it is likely that these recommendations will reduce unnecessary costs without impacting outcomes.
Given the substantial reduction in overall mortality, breast cancer screening is an integral part of women’s health. Providers in obstetrics and gynecology are often the primary source of education and the ordering team for breast cancer screening. Thus, it is critical for us to stay current on the recommendations for screening as well as the identification of high-risk women, allowing for well-informed decisions regarding individualized screening.
Dr. Ritu Salani is associate professor in gynecologic oncology at The Ohio State University, Columbus. Dr. Monica Hagan Vetter is a third-year resident in ob.gyn. at The Ohio State University. They reported having no financial disclosures.
For asymptomatic women at average risk of breast cancer, the American Cancer Society recommends annual mammograms from age 45 until age 54, with a transition to biennial screening mammography starting at age 55, according to new guidelines published Oct. 20.
This is the first time the American Cancer Society (ACS) has updated its breast cancer screening guidelines since 2003. The new version makes several changes, including shifting the start of annual mammography from age 40 to 45 years, and increasing the suggested screening interval for postmenopausal women (JAMA. 2015;314[15]:1599-1614. doi:10.1001/jama.2015.12783).
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
For the first time, the guidelines address the question of when to stop routine mammography, recommending a halt to routine screening for women with a life expectancy under 10 years. The ACS guidelines also recommend against clinical breast examinations at any age.
These changes bring the ACS guidelines more into line with recommendations from the U.S. Preventive Services Task Force, Dr. Nancy L. Keating and Dr. Lydia E. Pace, both of Brigham and Women’s Hospital, Boston, wrote in an editorial accompanying the report.
The two organizations are now in agreement on most recommendations and emphasize that breast cancer screening decisions should be individualized to reflect a woman’s values and preferences, not just her underlying risk. Both sets of recommendations also give greater consideration to the potential harms of mammography: overdiagnosis and overtreatment of indolent breast cancers, as well as false-positive results, additional imaging studies, and unnecessary biopsies.
The ACS updated the guideline after noting that new evidence had accumulated from long-term follow-up of both randomized controlled trials and population-based screening programs. The guideline development group, which included four clinicians, two biostatisticians, two epidemiologists, an economist, and two patient representatives, based its revised recommendations on an independent systemic evidence review of the breast cancer screening literature conducted by the Duke University Evidence Synthesis Group, as well as an analysis screening interval and outcomes from the Breast Cancer Surveillance Consortium.
For asymptomatic women at average risk of developing breast cancer, the ACS guideline makes the following recommendations:
Begin routine annual screening mammography at age 45 years (rather than age 40). Assessing the burden of breast cancer by 5-year rather than 10-year age categories demonstrated that the risk/benefit profiles of women aged 40-44 years differed markedly from those of older women and no longer warranted a recommendation to begin screening at age 40, wrote Dr. Kevin C. Oeffinger of Memorial Sloan Kettering Cancer Center, New York, and his associates in the ACS Guideline Development Group.
However, the ACS encourages clinicians to discuss breast cancer screening with patients “around the age of 40 years.” Women who want to begin annual screening mammography before age 45, based on a clear consideration of the trade-offs, should be given that choice, they wrote.
“Some women will value the potential early detection benefit and will be willing to accept the risk of additional testing,” Dr. Oeffinger and his associates wrote. “Other women will choose to defer beginning screening, based on the relatively lower risk of breast cancer.”
Women aged 45-54 years should receive annual screening mammography and at age 55 women should transition to biennial screening. The relative benefits of annual screening decline after menopause and as women age, and the majority of women are postmenopausal at age 55. At the same time, the relative harms of annual screening increase at this age, because the chance of false-positive results rises as the number of screenings rises. However, women who prefer to continue annual screening after age 55 should be given that opportunity, according to the ACS guidelines.
Women should continue screening mammography as long as their overall health is good and they have a life expectancy of 10 years or longer. Breast cancer incidence continues to increase with age until the age of 75-79 years, and mammography’s sensitivity and specificity improve with increasing age, so screening mammography in this age group will likely reduce breast cancer deaths. However, the authors noted that recent studies have raised concerns that older women with serious, or even terminal disorders, are still subjected to mammograms even though it will not increase their life expectancy or improve their quality of life.
“Health and life expectancy, not simply age, must be considered in screening decisions,” Dr. Oeffinger and his associates wrote.
Clinical breast examination is no longer recommended at any age. Historically, the ACS had advised periodic clinical breast exams for women younger than 40 and annual exams for women 40 and older. But there is no evidence that these exams, whether they are performed alone or in conjunction with mammography, enhance the detection of breast cancer, according to the guidelines.
Given that clinical breast exams are somewhat time consuming, “clinicians should use this time instead for ascertaining family history and counseling women regarding the importance of being alert to breast changes and the potential benefits, limitations, and harms of screening mammography,” the authors wrote.
“This new recommendation should not be interpreted to discount the potential value of clinical breast exams in low-resource settings where mammography screening may not be feasible,” they added.
In the accompanying editorial, Dr. Keating and Dr. Pace called this recommendation “a marked deviation from prior ACS guidelines and a stronger statement than that of the USPSTF,” which states only that the evidence is insufficient to recommend for or against clinical breast exams.
They noted that the majority of women who are diagnosed as having breast cancer “will do well regardless of whether their cancer was found by mammography.”
According to the most recent data, approximately 85% of women in their 40s and 50s who die of breast cancer would have died regardless of mammography screening. And even that 15% relative benefit translates to a very small absolute benefit: only 5 of 10,000 women in their 40s and 10 of 10,000 women in their 50s are likely to have a breast cancer death prevented by regular mammography, Dr. Keating and Dr. Pace wrote (JAMA 2015;314[15]:1569-71).
“It is important to remember and emphasize with average-risk women older than 40 years that there is no single right answer to the question ‘Should I have a mammogram?’ ” they wrote.
The American Cancer Society and the National Cancer Institute sponsored this work. Dr. Oeffinger reported having no relevant financial disclosures, and his associates reported ties to numerous industry sources.
For asymptomatic women at average risk of breast cancer, the American Cancer Society recommends annual mammograms from age 45 until age 54, with a transition to biennial screening mammography starting at age 55, according to new guidelines published Oct. 20.
This is the first time the American Cancer Society (ACS) has updated its breast cancer screening guidelines since 2003. The new version makes several changes, including shifting the start of annual mammography from age 40 to 45 years, and increasing the suggested screening interval for postmenopausal women (JAMA. 2015;314[15]:1599-1614. doi:10.1001/jama.2015.12783).
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
For the first time, the guidelines address the question of when to stop routine mammography, recommending a halt to routine screening for women with a life expectancy under 10 years. The ACS guidelines also recommend against clinical breast examinations at any age.
These changes bring the ACS guidelines more into line with recommendations from the U.S. Preventive Services Task Force, Dr. Nancy L. Keating and Dr. Lydia E. Pace, both of Brigham and Women’s Hospital, Boston, wrote in an editorial accompanying the report.
The two organizations are now in agreement on most recommendations and emphasize that breast cancer screening decisions should be individualized to reflect a woman’s values and preferences, not just her underlying risk. Both sets of recommendations also give greater consideration to the potential harms of mammography: overdiagnosis and overtreatment of indolent breast cancers, as well as false-positive results, additional imaging studies, and unnecessary biopsies.
The ACS updated the guideline after noting that new evidence had accumulated from long-term follow-up of both randomized controlled trials and population-based screening programs. The guideline development group, which included four clinicians, two biostatisticians, two epidemiologists, an economist, and two patient representatives, based its revised recommendations on an independent systemic evidence review of the breast cancer screening literature conducted by the Duke University Evidence Synthesis Group, as well as an analysis screening interval and outcomes from the Breast Cancer Surveillance Consortium.
For asymptomatic women at average risk of developing breast cancer, the ACS guideline makes the following recommendations:
Begin routine annual screening mammography at age 45 years (rather than age 40). Assessing the burden of breast cancer by 5-year rather than 10-year age categories demonstrated that the risk/benefit profiles of women aged 40-44 years differed markedly from those of older women and no longer warranted a recommendation to begin screening at age 40, wrote Dr. Kevin C. Oeffinger of Memorial Sloan Kettering Cancer Center, New York, and his associates in the ACS Guideline Development Group.
However, the ACS encourages clinicians to discuss breast cancer screening with patients “around the age of 40 years.” Women who want to begin annual screening mammography before age 45, based on a clear consideration of the trade-offs, should be given that choice, they wrote.
“Some women will value the potential early detection benefit and will be willing to accept the risk of additional testing,” Dr. Oeffinger and his associates wrote. “Other women will choose to defer beginning screening, based on the relatively lower risk of breast cancer.”
Women aged 45-54 years should receive annual screening mammography and at age 55 women should transition to biennial screening. The relative benefits of annual screening decline after menopause and as women age, and the majority of women are postmenopausal at age 55. At the same time, the relative harms of annual screening increase at this age, because the chance of false-positive results rises as the number of screenings rises. However, women who prefer to continue annual screening after age 55 should be given that opportunity, according to the ACS guidelines.
Women should continue screening mammography as long as their overall health is good and they have a life expectancy of 10 years or longer. Breast cancer incidence continues to increase with age until the age of 75-79 years, and mammography’s sensitivity and specificity improve with increasing age, so screening mammography in this age group will likely reduce breast cancer deaths. However, the authors noted that recent studies have raised concerns that older women with serious, or even terminal disorders, are still subjected to mammograms even though it will not increase their life expectancy or improve their quality of life.
“Health and life expectancy, not simply age, must be considered in screening decisions,” Dr. Oeffinger and his associates wrote.
Clinical breast examination is no longer recommended at any age. Historically, the ACS had advised periodic clinical breast exams for women younger than 40 and annual exams for women 40 and older. But there is no evidence that these exams, whether they are performed alone or in conjunction with mammography, enhance the detection of breast cancer, according to the guidelines.
Given that clinical breast exams are somewhat time consuming, “clinicians should use this time instead for ascertaining family history and counseling women regarding the importance of being alert to breast changes and the potential benefits, limitations, and harms of screening mammography,” the authors wrote.
“This new recommendation should not be interpreted to discount the potential value of clinical breast exams in low-resource settings where mammography screening may not be feasible,” they added.
In the accompanying editorial, Dr. Keating and Dr. Pace called this recommendation “a marked deviation from prior ACS guidelines and a stronger statement than that of the USPSTF,” which states only that the evidence is insufficient to recommend for or against clinical breast exams.
They noted that the majority of women who are diagnosed as having breast cancer “will do well regardless of whether their cancer was found by mammography.”
According to the most recent data, approximately 85% of women in their 40s and 50s who die of breast cancer would have died regardless of mammography screening. And even that 15% relative benefit translates to a very small absolute benefit: only 5 of 10,000 women in their 40s and 10 of 10,000 women in their 50s are likely to have a breast cancer death prevented by regular mammography, Dr. Keating and Dr. Pace wrote (JAMA 2015;314[15]:1569-71).
“It is important to remember and emphasize with average-risk women older than 40 years that there is no single right answer to the question ‘Should I have a mammogram?’ ” they wrote.
The American Cancer Society and the National Cancer Institute sponsored this work. Dr. Oeffinger reported having no relevant financial disclosures, and his associates reported ties to numerous industry sources.
FROM JAMA
Key clinical point: The American Cancer Society recommends annual mammograms for average-risk, asymptomatic women aged 45-54 years.
Major finding: The risk/benefit profiles of women aged 40-44 years differed markedly from those of older women and no longer warranted a recommendation to begin annual mammographic screening at age 40.
Data source: An update of the 2003 ACS guideline on breast cancer screening for women at average risk, based on a review of current evidence and an analysis of registry data for 15,440 women diagnosed during a 15-year period.
Disclosures: The American Cancer Society and the National Cancer Institute sponsored this work. Dr. Oeffinger reported having no relevant financial disclosures, and his associates reported ties to numerous industry sources.
